KZR Nasdaq· Kezar Life Sciences Inc.
FundamentalsNews digest Peer analysis
KZR Nasdaq· Kezar Life Sciences Inc.
Earnings report Q3 2023

Kezar Life Sciences Reports $7 Million in Collaboration Revenue for the Quarter

Segments of revenue

Kezar Life Sciences reported collaboration revenue of $7 million for the latest quarter. This revenue was generated through partnerships and collaborations with other companies in the biotechnology industry.


The company's collaboration revenue of $7 million for the quarter demonstrates its ability to attract partners and generate revenue through strategic alliances. This indicates that Kezar Life Sciences has valuable intellectual property and expertise that is sought after by other industry players. The increase in collaboration revenue compared to the previous quarter suggests that the company's partnerships are gaining traction and contributing to its financial performance.


Kezar Life Sciences reported a net loss of $23.1 million for the quarter. This loss is primarily attributed to the company's high research and development expenses, which amounted to $23.7 million. While it is expected for a clinical-stage biotechnology company to have significant R&D expenses, the company needs to carefully manage its costs to ensure sustainable growth and profitability.


Kezar Life Sciences has not yet generated product sales and has experienced operating losses since its inception. As of September 30, 2023, the company had an accumulated deficit of $318.5 million. To fully implement its business plan and continue its research and development activities, the company will need to raise additional capital. Kezar Life Sciences intends to raise capital through the issuance of additional equity, potential borrowings, strategic alliances, and licensing transactions. The recent Everest Collaboration, entered into in September 2023, is an example of the company's efforts to secure funding and advance its research.


Kezar Life Sciences reported collaboration revenue of $7 million for the latest quarter, indicating successful partnerships and revenue generation. However, the company also reported a net loss of $23.1 million, primarily due to high research and development expenses. Kezar Life Sciences will need to carefully manage its costs and raise additional capital to support its ongoing research and development activities. The company's ability to attract partners and secure funding through collaborations is a strength, but it also highlights the company's reliance on external funding sources. Overall, Kezar Life Sciences' financial performance in the latest quarter reflects both positive revenue growth and the challenges associated with being a clinical-stage biotechnology company.

Source documents

Form 10-Q  filed on Nov 13, 2023
22 pages scanned

Reference data

Company financials Q3 revenue 0
Analyst estimates Q3 EPS beat by 0.97%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.